C-VLCMReneuBio
small molecules, neural stem cells, aged brain screening
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VLCM
C-VLCMC-VLCMsmall molecules, neural stem cells, aged brain screening
0-100 chain-logic scale · 15 dimensions · scored on public evidence
ReneuBio small molecules, neural stem cells, aged brain screening
ReneuBio Inc. is developing medicines for age-related brain disorders including chemobrain, stroke, and Alzheimer's disease. The company aims to restore the aging brain's ability to heal by reactivating dormant neural stem cells. Its innovation engine screens old cells and old brains to identify therapeutic targets directly in aged brain tissue.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
ReneuBio — Early mechanism · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic